increasingly used for moderate-to-severe CD Antibiotics: Metronidazole, ciprofloxacin for perianal disease, fistulae, abscesses Coding Impact of Biologic Therapy When a patient is receiving biologic therapy for Crohns disease, coders should verify: HCPCS code for the specific biologic agent (J1745, J3357, J3380, J7999) is separately reported for the infusion encounter Infusion administration code (CPT 96413, 96415) is reported with the biologic J-code Long-term use of immunosuppressants should be captured with Z79.899 (long-term use of other medication) when relevant Biologic use combined with Crohns disease supports HCC 35 mapping and higher risk scores When corticosteroid use (prednisone, budesonide) extends beyond 90 days, assign Z79.52 (long-term use of systemic steroids)
intramuscular route: count injections given Visit 4 (week 52) Anamnesis: record lifestyle habits and use of alcohol Symptoms: record paresthesia, asthenia, loss or reduction of appetite, sadness or change in level of happiness, and concomitant pharmacological treatment Physical examination: for Hunters glositis, positional and vibrational sensitivity Record concomitant treatment Questionnaires: EuroQoL-5D, satisfaction and preferences Assessment of haemogram and serum vitamin B12 concentration Assessment of adverse effects Assess adherence to treatment: oral route count number of vials used
Lack of either FOLIC ACID or VITAMIN B12 can create anaemias
Dans un contexte de croissance dmographique et de diversification des services mdicaux offerts par le CHR de Sokod, lactivit du laboratoire ne cesse d'augmenter
.webp)
